Matthew Brown

Matthew Brown

Auto-generated profile, based on publicly available information

Matthew Brown

Sinai Immunology Review Project, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Immunity
Verified
Journal Article
Closed access
NVNicolas Vabret
Nicolas Vabret
GBGraham Britton
Graham Britton
CGConor Gruber
Conor Gruber
SHSamarth Hegde
Samarth Hegde
JKJoel Kim
Joel Kim
ULUri Laserson
Uri Laserson

13 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMatthew Brown
Matthew Brown
WZWanbin Zhang
Wanbin Zhang
DYDeyue Yan
Deyue Yan
RKRajath Kenath
Rajath Kenath
LLLe Le
Le Le
KPKien Pham
Kien Pham
Treating pancreatic ductal adenocarcinoma (PDAC) remains a major hurdle in the field of oncology. Less than half of patients respond to frontline chemotherapy and the pancreatic tumor microenvironment limits the efficacy of immunotherapeutic approaches. Targeted therapies could serve as effective treatments to enhance the clinical response rate. One potential therapeutic target is survivin, a protein that is normally expressed during embryonic and fetal development and has a critical impact on cell cycle control and apoptosis. In adulthood, survivin is not present in most normal adult cells, but is significantly re-expressed in tumor tissues. In PDAC, elevated survivin expression is correlated with treatment resistance and lower patient survival, although the underlying mechanisms of survivin’s action in this type of cancer is poorly understood. Using patient derived xenografts of PDAC and their corresponding primary pancreatic cancer lines (PPCL-46 and PPCL-LM1) possessing increased expression of survivin, we aimed to evaluate the therapeutic response of a novel survivin inhibitor, UFSHR, with respect to survivin expression and the tumorigenic characteristics of PDAC. Cell viability and apoptosis analyses revealed that repressing survivin expression by UFSHR or YM155, a well-known inhibitor of survivin, in PPCLs effectively reduces cell proliferation by inducing apoptosis. Tumor cell migration was also hindered following treatment with YM155 and UFSHR. In addition, both survivin inhibitors, particularly UFSHR, effectively reduced progression of PPCL-46 and PPCL-LM1 tumors, when compared to the untreated cohort. Overall, this study provides solid evidence to support the critical role of survivin in PDAC progression and proposes a novel survivin inhibitor UFSHR that can become an alternative strategy for this type of cancer.

12 January 2024 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MBMatthew Brown
Matthew Brown
NVNicolas Vabret
Nicolas Vabret

1 September 2020 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MBMatthew Brown
Matthew Brown

13 June 2023 in Immunity
Verified
Journal Article
Closed access
MBMatthew Brown
Matthew Brown
MTMichelle A. Tran
Michelle A. Tran
NBNina Bhardwaj
Nina Bhardwaj

8 December 2025 in Research Square
Verified
Preprint
Open access
PDF file
GMGuillaume Mestrallet
Guillaume Mestrallet
MBMatthew Brown
Matthew Brown
NVNatalie Vaninov
Natalie Vaninov
NCNam Woo Cho
Nam Woo Cho
LVLeandra Velazquez
Leandra Velazquez
NBNina Bhardwaj
Nina Bhardwaj
Colorectal cancer (CRC) accounts for 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide. Immunotherapies have significantly advanced over the past decades, marking a major breakthrough in cancer treatment. While anti-PD-1 therapy is utilized in both local and advanced disease, up to 50% of mismatch repair deficient (MMRd) and most mismatch repair proficient (MMRp) CRC fail to respond. Using orthotopic animal and patient-derived models of CRC, along with single cell and spatial analyses, we determined that colocalization and interactions between MHC + C1Q + CXCL9 + macrophages and TCF + PRF1 + T cell subsets are associated with control of tumor growth during anti-PD-1 treatment. In contrast, resistance is associated with upregulation of TIM3, LAG3, TIGIT, and PD-1 expression on T cells, and tumor infiltration by immunosuppressive TREM2 + macrophages and monocytes in T cell excluded zones. A novel combinatorial checkpoint blockade targeting TREM2, LAG3, CTLA4, and PD-1 achieves up to 100% tumor clearance in MMRd CRC and > 70% in MMRp CRC models, compared to 0% with anti-PD-1 monotherapy. This approach induces durable anti-tumor immune memory, mediated by coordinated interactions among MHC + macrophages, CD4+/CD8 + T cells, and TCF + T cells. It also reduced infiltration by immunosuppressive myeloid cells and T cell exhaustion. Together this study identifies key T cell and macrophage subsets mediating the efficacy of immunotherapy in overcoming immune escape in both MMRd and MMRp CRC settings.